Nexvet Biopharma (NVET) Provides Additional NV-01 Data at Investor Day; Cowen Reiterates Outperform

Cowen reiterated an Outperform rating and $13.00 price target on Nexvet Biopharma (NASDAQ: NVET) following investor meetings. Nexvet provided additional data from the pivotal NV-01 trial for which positive results were announced last week. NV-01 met statistical significance in 12 of the 17 endpoints; missed significance by small amount in 3 endpoints, and did not show significance in 2 of the endpoints.

Analyst Steve Scala commented, "Nexvet's investor meeting yesterday reinforced the favorable outlook for use of mAbs in companion animals. NV-01 and NV -02 appear well positioned to be first to market for OA pain in dogs and cats. Launch in our model now assumed early 2019."

For an analyst ratings summary and ratings history on Nexvet Biopharma click here. For more ratings news on Nexvet Biopharma click here.

Shares of Nexvet Biopharma closed at $4.08 yesterday.

You May Also Be Interested In

• TD Cowen Reiterates Buy Rating on Tesla (TSLA), well-positioned to scale in US AV market
• KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating